Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients

Trial Profile

A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs ARO-HBV (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2019 Planned number of patients changed from 86 to 102.
    • 09 Nov 2018 According to an Arrowhead Pharmaceuticals media release, data from this study were presented at the Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
    • 09 Nov 2018 According to an Arrowhead Pharmaceuticals media release, dosing in the single-ascending dose (SAD) portion of the study is complete.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top